✦ LIBER ✦

A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

✍ Scribed by Mohammad Ebrahim Parsanezhad; Saeed Alborzi; Bahia Namavar Jahromi

Publisher: Springer
Year: 2004
Tongue: English
Weight: 131 KB
Volume: 269
Category: Article
ISSN: 0003-9128
DOI: 10.1007/s00404-002-0437-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of Hypericum e

Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: A double-blind, randomized, placebo-controlled clinical trial

✍ Ralf Uebelhack; Joerg Gruenwald; Hans-Joachim Graubaum; Regina Busch 📂 Article 📅 2004 🏛 Springer Healthcare Communications 🌐 English ⚖ 106 KB

Efficacy and safety of high-dose pravast

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

✍ James H. Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a place

Efficacy and safety of risperidone in th

Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial

✍ Dieter Naber; Andrew Greenspan; Andreas Schreiner 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 74 KB

The effect of moderate-dose corticostero

The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial

✍ Chung-E Tseng; Jill P. Buyon; Mimi Kim; H. Michael Belmont; Meggan Mackay; Betty 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## Objective Serial measurements of anti–double‐stranded DNA (anti‐dsDNA) and complement are routine in the management of systemic lupus erythematosus (SLE), but their utility as biomarkers in preemptive treatment to prevent flares remains a subject of controversy. We hypothesized that

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 3 views

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal